Change in Maximal Left Atrial Volume Index (LAVI) and Left Ventricular End Diastolic Volume Index (LVEDVI)
ventricular diastolic stiffness, PP, arterial stiffness
Cardiac magnetic resonance imaging–estimated change in maximal LAVI was greater in patients assigned to receive sacubitril/valsartan (6.9 mL/mIn post hoc analyses, we found that sacubitril/valsartan was associated with a reduction in left atrial and left ventricular diastolic stiffness index compared to valsartan. PP, arterial stiffness, and systemic vascular resistance were also reduced, while arterial compliance was increased in the sacubitril/valsartan vs valsartan treatment groups (